Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Nanogam 100 mg/ml in Primary Immunodeficiency
NCT01985373Phase 3Completed
- Sponsor
- Prothya Biosolutions
- Start
- Dec 2013
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Nanogam in primary immunodeficiency (PI), sponsored by Prothya Biosolutions. Started Dec 2013; status: completed.
02
Drugs
Nanogam
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT01985373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01985373.